OBJECTIVE: The aim of this study was to determine the gene is spelled excision repair cross-complementing gene 1 (ERCC1) RNA-expression in peripheral blood as a non-invasive molecular predictor of response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. BACKGROUND: Only patients with locally advanced cancer of the esophagus with a major histopathological response to neoadjuvant radio-chemotherapy benefit from this treatment. No non-invasive molecular marker exists that can reliably predict response to neoadjuvant therapy in this disease. To improve the treatment of patients with cancer of the esophagus, molecular predictors of response are desperately needed. METHODS: Blood samples were drawn from 29 patients with esophageal cancer prior to neoadjuvant radio-chemotherapy. After extraction of cellular tumor-RNA from blood samples, quantitative expression analysis of ERCC1 was done by real-time reverse transcription polymerase chain reaction. RESULTS: Nineteen (65.5%) patients showed a minor and ten (34.5%) a major histopathological response to neoadjuvant therapy. ERCC1 expression in blood of patients was detectable in 82.8%. The median ERCC1 expression was 0.62 (minimum 0.00, maximum 2.48) in minor responders and 0.24 (minimum 0.00, maximum 0.45) in major responders (p = 0.004). No significant associations were detectable between ERCC1 levels and patients' clinical variables. Relative ERCC1 levels above 0.452 were not associated with major histopathological response (sensitivity, 68.4; specificity, 100%), and 13 of 19 patients with minor response could be unequivocally identified. CONCLUSION: Minor responders to the applied therapy show a significant higher ERCC1 expression level in their blood compared to major responders. ERCC1 appears to be a highly specific non-invasive predictor of response to neoadjuvant therapy in esophageal cancer.
OBJECTIVE: The aim of this study was to determine the gene is spelled excision repair cross-complementing gene 1 (ERCC1) RNA-expression in peripheral blood as a non-invasive molecular predictor of response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. BACKGROUND: Only patients with locally advanced cancer of the esophagus with a major histopathological response to neoadjuvant radio-chemotherapy benefit from this treatment. No non-invasive molecular marker exists that can reliably predict response to neoadjuvant therapy in this disease. To improve the treatment of patients with cancer of the esophagus, molecular predictors of response are desperately needed. METHODS: Blood samples were drawn from 29 patients with esophageal cancer prior to neoadjuvant radio-chemotherapy. After extraction of cellular tumor-RNA from blood samples, quantitative expression analysis of ERCC1 was done by real-time reverse transcription polymerase chain reaction. RESULTS: Nineteen (65.5%) patients showed a minor and ten (34.5%) a major histopathological response to neoadjuvant therapy. ERCC1 expression in blood of patients was detectable in 82.8%. The median ERCC1 expression was 0.62 (minimum 0.00, maximum 2.48) in minor responders and 0.24 (minimum 0.00, maximum 0.45) in major responders (p = 0.004). No significant associations were detectable between ERCC1 levels and patients' clinical variables. Relative ERCC1 levels above 0.452 were not associated with major histopathological response (sensitivity, 68.4; specificity, 100%), and 13 of 19 patients with minor response could be unequivocally identified. CONCLUSION: Minor responders to the applied therapy show a significant higher ERCC1 expression level in their blood compared to major responders. ERCC1 appears to be a highly specific non-invasive predictor of response to neoadjuvant therapy in esophageal cancer.
Authors: Huan Xi; Stephan E Baldus; Ute Warnecke-Eberz; Jan Brabender; Susanne Neiss; Ralf Metzger; Frederike C Ling; Hans P Dienes; Elfriede Bollschweiler; Stefan Moenig; Rolf P Mueller; Arnulf H Hoelscher; Paul M Schneider Journal: Clin Cancer Res Date: 2005-12-01 Impact factor: 12.531
Authors: Hiroshi Higashi; Daniel Vallböhmer; Ute Warnecke-Eberz; Shuichi Hokita; Huan Xi; Jan Brabender; Ralf Metzger; Stephan E Baldus; Shoji Natsugoe; Takashi Aikou; Arnulf H Hölscher; Paul M Schneider Journal: Anticancer Res Date: 2006 May-Jun Impact factor: 2.480
Authors: Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz Journal: J Clin Oncol Date: 2001-12-01 Impact factor: 44.544
Authors: Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher Journal: Ann Surg Date: 2005-11 Impact factor: 12.969
Authors: R Metzger; C G Leichman; K D Danenberg; P V Danenberg; H J Lenz; K Hayashi; S Groshen; D Salonga; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; B Konda; L Leichman Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Feng-Ming Hsu; Jason Chia-Hsien Cheng; Yih-Leong Chang; Jang-Ming Lee; Albert C Koong; Eric Y Chuang Journal: Sci Rep Date: 2015-05-18 Impact factor: 4.379